Enzymatic Degradation Inhibitors: Vigabatrin
Structurally, vigabatrin is a direct GABA analogue. Its primary pharmacological target is GABA transaminase, the enzyme responsible for breaking down (catabolizing) GABA.
The drug exerts its pharmacological effect by binding irreversibly to this enzyme, thereby inhibiting its function. This leads to a marked increase in the concentration of the inhibitory neurotransmitter directly within brain tissue. The drug exhibits a broad-spectrum anticonvulsant profile.
Main Indications:
- Treatment of partial-onset seizures.
- Prevention of generalized tonic-clonic seizures.
Neuronal Reuptake Blockers: Tiagabine
This synthetic compound does not occur naturally. The mechanism of action of tiagabine differs fundamentally from the previous agent. It targets and blocks the specialized transporter system responsible for the physiological reuptake of GABA back into the neuron.
By inhibiting neuronal reuptake from the synaptic cleft, the drug allows the neurotransmitter to remain in the active zone longer, increasing its local concentration.
Clinically, this agent is primarily used as an adjunctive drug in baseline therapy for preventing both partial and generalized epileptic seizures.
Important Clinical Considerations:
- The drug can potentiate (significantly enhance) the effects of other central nervous system depressants, including benzodiazepines, barbiturates, and ethanol.
- Adverse reactions may include marked sedation, drowsiness, depressive disorders, and psychotic states.
Drugs with Atypical Mechanisms: Gabapentin
Gabapentin (also known by the brand name Neurontin) was originally developed as a lipophilic GABA analogue designed to stimulate $ ext{GABA}_A$ receptors. However, subsequent studies revealed that it possesses no direct GABA-mimetic activity.
Its true mechanism of action involves presynaptic terminals. The primary molecular target is the $\alpha_2\delta$ subunit of voltage-gated calcium channels (N-type). By blocking these channels, the drug prevents $ ext{Ca}^{2+}$ influx into the cell during membrane depolarization, thereby reducing the pathological release of excitatory neurotransmitters.
Additional hypotheses suggest the drug may also inhibit the transport of excitatory amino acids and modestly stimulate endogenous GABA release.
Clinical Applications and Adverse Effects:
- Prescribed as adjunctive therapy for partial seizures.
- Demonstrates high clinical efficacy in treating neuropathic pain syndromes.
- Adverse effect profile includes dizziness, ataxia (impaired coordination), headaches, tremor, and somnolence.